双鹭药业 (002038.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−48.1x

Market Cap

CNY 6.54B

MomentumView details →

1D Return

−10.03%

YTD Return

−20.22%

RSI (14)

46.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−48.1x

Market Cap

CNY 6.54B

RSI (14)

46.0

MomentumView details →

1D Return

−10.03%

YTD Return

−20.22%

ProfitabilityView details →

Gross Margin

63.31%

Net Margin

−81.02%

EBITDA Margin

−18.97%

ROE (TTM)

−9.41%

ROA (TTM)

−8.21%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

+1.26%

EPS YoY

—

FCF YoY

+178.08%

Revenue CAGR 3Y

−15.95%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

3.38x

Quick Ratio

2.47x

Div Yield

0.17%

Div Rate

CNY 0.01

Div Growth 1Y

−50.00%

Financials snapshotView financials →

Revenue (TTM)

591.59M

Net Income (TTM)

−479.28M

Op. CF (TTM)

372.31M

Latest newsMore news →

Shuanglu Pharmaceutical reported a net loss of 255 million yuan attributable to shareholders for the first half of 2026, turning from a profit of 121 million yuan in the same period of 2025.11d ago

Shuanglu Pharmaceutical's finance head Ji Li resigned and Wei Yanfeng was appointed as the new finance head.46d ago

Similar companies

天铁科技300587.SZ 尔康制药300267.SZ 万顺新材300057.SZ 华统股份002840.SZ 天奇股份002009.SZ 新联电子002546.SZ Find similar companies →

Latest newsMore news →

Shuanglu Pharmaceutical reported a net loss of 255 million yuan attributable to shareholders for the first half of 2026, turning from a profit of 121 million yuan in the same period of 2025.11d ago Shuanglu Pharmaceutical's finance head Ji Li resigned and Wei Yanfeng was appointed as the new finance head.46d ago